98%
921
2 minutes
20
Despite the availability of numerous approved immunotherapies for various cancers, durable progression-free survival remains relatively uncommon among patients with advanced cancer. As research into immunotherapy intensifies, the heterogeneity and complexity of the tumor microenvironment (TME) have emerged as critical determinants of treatment response and a major obstacle to understanding tumor resistance mechanisms. Recent advances in spatially resolved transcriptomics (SRT) enable transcriptome-wide measurement of gene expression while preserving essential spatial information, which supports the characterization of the features of the TME. This review outlines key challenges in cancer immunotherapy and emphasizes the importance of the TME in determining therapeutic efficacy. SRT strategies suitable is systematically introduced for TME profiling, comparing their relative advantages and limitations. Additionally, bioinformatics tools and methods used to reconstruct spatial tissue patterns are discussed from SRT data. Furthermore, how SRT is explored can enhance the understanding of the complexity and heterogeneity of the TME, facilitate the identification of novel therapeutic targets, and advance biomarker discovery to refine personalized treatment strategies for diverse cancer patients. Finally, future perspectives on the application of SRT in cancer immunotherapy and addressing the associated challenges are provided.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/smtd.202500770 | DOI Listing |
EMBO J
September 2025
Department of Infectious Diseases, Medical Research Institute, Zhongnan Hospital of Wuhan University; Frontier Science Center for Immunology and Metabolism, Taikang Center for Life and Medical Sciences; Wuhan University, Wuhan, 430071, China.
Inadequate antigen presentation by MHC-I in tumor microenvironment (TME) is a common immune escape mechanism. Here, we show that glycine decarboxylase (GLDC), a key enzyme in glycine metabolism, functions as an inhibitor of MHC-I expression in EGFR-activated tumor cells to induce immune escape by a mechanism independent of its enzymatic activity. Upon EGFR activation, GLDC is phosphorylated by SRC and subsequently translocated to the nucleus in human NSCLC cells.
View Article and Find Full Text PDFNat Rev Cancer
September 2025
Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Neurotoxicity is a common and potentially severe adverse effect from conventional and novel cancer therapy. The mechanisms that underlie clinical symptoms of central and peripheral nervous system injury remain incompletely understood. For conventional cytotoxic chemotherapy or radiotherapy, direct toxicities to brain structures and neurovascular damage may result in myelin degradation and impaired neurogenesis, which eventually translates into delayed neurodegeneration accompanied by cognitive symptoms.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, Divisions of Surgical Oncology, Colon and Rectal Surgery, Immunotherapy, University of Louisville School of Medicine, Louisville, KY, USA.
Nat Cell Biol
September 2025
NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin, China.
The colon exhibits higher propensity for tumour development than ileum. However, the role of immune microenvironment differences in driving this disparity remains unclear. Here, by comparing paired ileum and colon samples from patients with colorectal cancer (CRC) and healthy donors, we identified ileum-enriched CD160CD8 T cells with previously unrecognized characteristics, including resistance to terminal exhaustion and strong clonal expansion.
View Article and Find Full Text PDFNat Cell Biol
September 2025
Department of Oncology, University of Lausanne, Lausanne, Switzerland.